Regulatory T cells expanded by rapamycin in vitro suppress colitis in an experimental mouse model

Journal of Gastroenterology

Volumn 47, Issue 4, 2012, Pages 366-376

  Ogino, Haruei ^a   Nakamura, Kazuhiko ^a   Iwasa, Tsutomu ^a   Ihara, Eikich ^a   Akiho, Hirotada ^a   Motomura, Yasuaki ^b   Akahoshi, Kazuya ^b   Igarashi, Hisato ^a   Kato, Masaki ^a   Kotoh, Kazuhiro ^a   Ito, Tetsuhide ^a   Takayanagi, Ryoichi ^a  

^a KYUSHU UNIVERSITY   (Japan)

^b ASO IIZUKA HOSPITAL   (Japan)

Author keywords

Colitis; Inflammatory bowel disease; Rapamycin; Regulatory T cells

Indexed keywords

ALPHA INTERFERON; INTERLEUKIN 17; MESSENGER RNA; RAPAMYCIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CD4+ T LYMPHOCYTE; COLITIS; CONTROLLED STUDY; DOWN REGULATION; DRUG MECHANISM; EX VIVO STUDY; FLOW CYTOMETRY; HISTOLOGY; IN VITRO STUDY; LYMPHOCYTE ACTIVATION; MONOTHERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SCID MOUSE; TOXICITY;

ANIMALS; CD4 LYMPHOCYTE COUNT; CELL CULTURE TECHNIQUES; COLITIS; COLON; CYTOKINES; IMMUNOSUPPRESSIVE AGENTS; MICE; MICE, INBRED BALB C; MICE, SCID; MODELS, ANIMAL; REAL-TIME POLYMERASE CHAIN REACTION; RNA, MESSENGER; SIROLIMUS; T-LYMPHOCYTES, REGULATORY;

EID: 84863098198     PISSN: 09441174     EISSN: 14355922     Source Type: Journal    
DOI: 10.1007/s00535-011-0502-y     Document Type: Article

References (27)

1. Strober W, Fuss I, Mannon P. The fundamental basis of inflammatory bowel disease. J Clin Invest. 2007;117:514-21. (Pubitemid 46348505)
2. Ardizzone S, Cassinotti A, Manes G, Porro GB. Immunomodu lators for all patients with inflammatory bowel disease? Therap Adv Gastroenterol. 2010;3:31-42.
3. Kahan BD, Camardo JS. Rapamycin: clinical results and future opportunities. Transplantation. 2001;72:1181-93. (Pubitemid 33026593)
4. Busca A, Locatelli F, Moscato D, Falda M. Sirolimus-related toxicity in stem cell transplantation. Biol Blood Marrow Transpl. 2005;11:647-9. (Pubitemid 41001640)
5. Abraham RT, Wiederrecht GJ. Immunopharmacology of rapamycin. Annu Rev Immunol. 1996;14:483-510. (Pubitemid 26130192)
6. Qu Y, Zhang B, Zhao L, Liu G, Ma H, Rao E, et al. The effect of immunosuppressive drug rapamycin on regulatory CD4+CD25+ Foxp3+ T cells in mice. Transpl Immunol. 2007;17:153-61.
7. Farkas S, Hornung M, Sattler C, Guba M, Steinbauer M, Anthuber M, et al. Rapamycin decreases leukocyte migration in vivo and effectively reduces experimentally induced chronic colitis. Int J Colorectal Dis. 2006;21:747-53. (Pubitemid 44524028)
8. Matsuda C, Ito T, Song J, Mizushima T, Tamagawa H, Kai Y, et al. Therapeutic effect of a new immunosuppressive agent, everolimus, on interleukin-10 gene-deficient mice with colitis. Clin Exp Immunol. 2007;148:348-59. (Pubitemid 46587591)
9. Kopf H, de la Rosa GM, Howard OM, Chen X. Rapamycin inhibits differentiation of Th17 cells and promotes generation of FoxP3+ T regulatory cells. Int Immunopharmacol. 2007;7:1819-24. (Pubitemid 350046435)
10. Ogino H, Nakamura K, Ihara E, Akiho H, Takayanagi R. CD4(+)CD25(+) regulatory T cells suppress Th17-responses in an experimental colitis model. Dig Dis Sci. 2011;56:376-86.
11. high regulatory T cells from leukapheresis products from ulcerative colitis patients, applicable to regulatory T-cell transfer therapy. Cytotherapy. 2008;10:698-710.
12. Lyones AB, Parish CR. Determination of lymphocyte division by flow cytometry. J Immunol Methods. 1994;171:131-7. (Pubitemid 24140219)
13. Mudter J, Wirtz S, Galle PR, Neurath MF. A new model of chronic colitis in SCID mice induced by adoptive transfer of CD62L+CD4+ T cells: insights into the regulatory role of interleukin-6 on apoptosis. Pathobiology. 2002;70:170-6. (Pubitemid 36184451)
14. Fantini MC, Becker C, Tubbe I, Nikolaev A, Lehr HA, Galle P, et al. Transforming growth factor b induced FoxP3+ regulatory T cells suppress Th1 mediated experimental colitis. Gut. 2006;55: 671-80.
15. Honda K, Nakamura K, Matsui N, Takahashi M, Kitamura Y, Mizutani T, et al. T helper 1-inducing property of IL-27/WSX-1 signaling is required for the induction of experimental colitis. Inflamm Bowel Dis. 2005;11:1044-52. (Pubitemid 41682560)
16. Kasajima A, Pavel M, Darb-Esfahani S, Noske A, Stenzinger A, Sasano H, et al. mTOR expression and activity patterns in gastroenteropancreatic neuroendocrine tumours. Endocr Relat Cancer. 2011;18:181-92.
17. Battaglia M, Stabilini A, Migliavacca B, Horejs-Hoeck J, Kaupper T, Roncarolo MG. Rapamycin promotes expansion of functional CD4+CD25+FOXP3+ regulatory T cells of both healthy subjects and type 1 diabetic patients. J Immunol. 2006; 177:8338-47. (Pubitemid 44893795)
18. Sakaguchi S. Regulatory T cells: key controllers of immunologic self-tolerance. Cell. 2000;101:455-8.
19. Takahashi T, Kuniyasu Y, Toda M, Sakaguchi N, Itoh M, Iwata M, et al. Immunologic self-tolerance maintained by CD25+CD4+ naturally anergic and suppressive T cells: induction of autoimmune disease by breaking their anergic/suppressive state. Int Immunol. 1998;10:1969-80. (Pubitemid 28566059)
20. + regulatory T cells. J Immunol. 2003;170:3939-43. (Pubitemid 36428153)
21. Maul J, Loddenkemper C, Mundt P, Berg E, Giese T, Stallmach A, et al. Peripheral and intestinal regulatory CD4+CD25(high) T cells in inflammatory bowel disease. Gastroenterology. 2005;128: 1868-78. (Pubitemid 40824698)
22. Takahashi M, Nakamura K, Honda K, Kitamura Y, Mizutani T, Araki Y, et al. An inverse correlation of human peripheral blood regulatory T cell frequency with the disease activity of ulcerative colitis. Dig Dis Sci. 2006;51:677-86.
23. Makita S, Kanai T, Oshima S, Uraushihara K, Totsuka T, Sawada T, et al. CD4+CD25bright T cells in human intestinal lamina propria as regulatory cells. J Immunol. 2004;173:3119-30. (Pubitemid 39142018)
24. Holmén N, Lundgren A, Lundin S, Bergin AM, Rudin A, Sjövall H, et al. Functional CD4+CD25 high regulatory T cells are enriched in the colonic mucosa of patients with active ulcerative colitis and increase with disease activity. Inflamm Bowel Dis. 2006;12:447-56.
25. Battaglia M, Stabilini A, Roncarolo MG. Rapamycin selectively expands CD4+CD25+FoxP3+ regulatory T cells. Blood. 2005;105: 4743-8.
26. Strauss L, Whiteside TL, Knights A. Selective survival of naturally occurring human CD4+CD25+Foxp3+ regulatory T cells cultured with rapamycin. J Immunol. 2007;178:320-9. (Pubitemid 46033615)
27. Gao W, Lu Y, El Essawy B. Contrasting effects of cyclosporine and rapamycin in de novo generation of alloantigen-specific regulatory T cells. Am J Transpl. 2007;7:1722-32. (Pubitemid 46905432)